• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years.BNT162b2 mRNA新冠疫苗在5岁以下儿童中的有效性。
J Clin Invest. 2023 Nov 1;133(21):e173329. doi: 10.1172/JCI173329.
2
Off-label prescription of BNT162b2 mRNA COVID-19 vaccine to <5-year-old children in the European Union.欧盟对5岁以下儿童进行BNT162b2 mRNA新冠疫苗的超说明书用药处方
Acta Paediatr. 2023 Feb;112(2):183-185. doi: 10.1111/apa.16442. Epub 2022 Jun 26.
3
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.两种 mRNA COVID-19 疫苗与灭活 COVID-19 疫苗序贯加强接种在 5-11 岁儿童中的反应原性和免疫原性比较。
J Med Virol. 2023 May;95(5):e28758. doi: 10.1002/jmv.28758.
4
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine.第三剂 BNT162b2 mRNA 疫苗的有效性。
J Infect Dis. 2022 Jan 5;225(1):30-33. doi: 10.1093/infdis/jiab556.
5
Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.mRNA-1273和BNT162b2疫苗在卡塔尔的有效性。
N Engl J Med. 2022 Feb 24;386(8):799-800. doi: 10.1056/NEJMc2117933. Epub 2022 Jan 19.
6
Why two doses of the BNT162b2 mRNA COVID-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA COVID-19 and other vaccines.为什么要接种两剂BNT162b2 mRNA新冠疫苗？一种加快疫苗接种进程的不同策略：单剂BNT162b2 mRNA新冠疫苗及其他疫苗。
Panminerva Med. 2022 Mar;64(1):131-132. doi: 10.23736/S0031-0808.21.04286-5. Epub 2021 Jan 22.
7
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.BNT162b2和mRNA-1273新冠疫苗在卡塔尔针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔变种的有效性
Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 2.
8
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.针对 COVID-19 mRNA 疫苗 BNT162b2 作为灭活 SARS-CoV-2 病毒疫苗异源加强针的疫苗有效性的证据综合和汇总分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856. doi: 10.1080/21645515.2023.2165856. Epub 2023 Feb 1.
9
More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.关于5至11岁儿童使用BNT162b2新冠疫苗的更多信息。
N Engl J Med. 2022 Mar 24;386(12):1192. doi: 10.1056/NEJMc2201556. Epub 2022 Mar 2.
10
More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.关于5至11岁儿童使用BNT162b2新冠疫苗的更多信息。
N Engl J Med. 2022 Mar 24;386(12):1191-1192. doi: 10.1056/NEJMc2201556. Epub 2022 Mar 2.

引用本文的文献

1
Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study.德国（CoVacU5）5 岁以下儿童接种 BNT162b2 mRNA COVID-19 疫苗后症状的性别差异：一项回顾性队列研究。
Biol Sex Differ. 2024 Sep 26;15(1):74. doi: 10.1186/s13293-024-00651-x.

本文引用的文献

1
Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.美国观察性队列研究：COVID-19 疫苗接种和既往 SARS-CoV-2 感染对 12 岁以下儿童感染奥密克戎和严重结局的影响。
Lancet Infect Dis. 2023 Nov;23(11):1257-1265. doi: 10.1016/S1473-3099(23)00272-4. Epub 2023 Jun 16.
2
Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.BNT162b2 信使 RNA COVID-19 疫苗与 5 岁以下儿童中其他获批疫苗的比较安全性。
JAMA Netw Open. 2022 Oct 3;5(10):e2237140. doi: 10.1001/jamanetworkopen.2022.37140.

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years.

作者信息

Strumann Christoph, Ranzani Otavio, Moor Jeanne, Berner Reinhard, Töpfner Nicole, Chao Cho-Ming, Moor Matthias B

机构信息

Institute of Family Medicine, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.

Barcelona Institute for Global Health, ISGlobal, Universitat Pompeu Fabra, Barcelona, Spain.

出版信息

J Clin Invest. 2023 Nov 1;133(21):e173329. doi: 10.1172/JCI173329.

DOI:10.1172/JCI173329
PMID:37669113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10617758/
Abstract
摘要